WallStSmart

Hinge Health, Inc. (HNGE)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 8671% more annual revenue ($56.69B vs $646.34M). NVS leads profitability with a 22.5% profit margin vs -78.9%. NVS earns a higher WallStSmart Score of 51/100 (C-).

HNGE

Avoid

34

out of 100

Grade: F

Growth: 7.3Profit: 3.5Value: 5.0Quality: 5.0
Piotroski: 3/9Altman Z: -2.69

NVS

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 9.0Value: 3.3Quality: 4.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for HNGE.

NVSSignificantly Overvalued (-68.7%)

Margin of Safety

-68.7%

Fair Value

$92.54

Current Price

$159.85

$67.31 premium

UndervaluedFair: $92.54Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HNGE2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
47.2%10/10

Revenue surging 47.2% year-over-year

Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$290.96B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
35.1%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
31.8%10/10

Strong operational efficiency at 31.8%

Profit MarginProfitability
22.5%9/10

Keeps 23 of every $100 in revenue as profit

Free Cash FlowQuality
$2.87B8/10

Generating 2.9B in free cash flow

Areas to Watch

HNGE4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Price/BookValuation
51.1x2/10

Trading at 51.1x book value

Return on EquityProfitability
-197.2%2/10

ROE of -197.2% — below average capital efficiency

EPS GrowthGrowth
-68.4%2/10

Earnings declined 68.4%

NVS4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
0.8%4/10

0.8% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Debt/EquityHealth
1.223/10

Elevated debt levels

PEG RatioValuation
4.152/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : HNGE

The strongest argument for HNGE centers on Revenue Growth, Debt/Equity. Revenue growth of 47.2% demonstrates continued momentum.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 31.8%.

Bear Case : HNGE

The primary concerns for HNGE are Piotroski F-Score, Price/Book, Return on Equity.

Bear Case : NVS

The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.

Key Dynamics to Monitor

HNGE profiles as a hypergrowth stock while NVS is a value play — different risk/reward profiles.

HNGE is growing revenue faster at 47.2% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor HEALTH INFORMATION SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NVS scores higher overall (51/100 vs 34/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Hinge Health, Inc.

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Hinge Health, Inc. develops health care software for joint and muscle health. The company is headquartered in San Francisco, California.

Visit Website →

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?